Compare SND & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SND | LYEL |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | 318 | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.0M | 195.8M |
| IPO Year | 2016 | 2021 |
| Metric | SND | LYEL |
|---|---|---|
| Price | $3.82 | $14.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $37.88 |
| AVG Volume (30 Days) | ★ 199.0K | 193.2K |
| Earning Date | 11-20-2026 | 11-04-2026 |
| Dividend Yield | ★ 6.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $330,153,000.00 | $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.13 | ★ N/A |
| Revenue Growth | ★ 6.03 | N/A |
| 52 Week Low | $2.09 | $7.20 |
| 52 Week High | $5.92 | $45.00 |
| Indicator | SND | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 21.77 | 75.02 |
| Support Level | $3.64 | $11.87 |
| Resistance Level | $5.39 | $14.97 |
| Average True Range (ATR) | 0.24 | 1.22 |
| MACD | -0.12 | 0.73 |
| Stochastic Oscillator | 3.62 | 77.65 |
Smart Sand Inc. is a fully integrated frac sand company providing mine-to-well site proppant supply and logistics. It produces Northern White frac sand for enhanced hydrocarbon recovery in oil and gas wells. The company offers products like Smart System, SmartBelt, SmartDepot Silo, and SmartPath Loader. It is expanding into industrial markets, including glass, ceramics, and renewable energy, while its main revenue comes from sand sales and logistics. The company has two reportable segments, Sand and SmartSystems. It derives maximum revenue from Sand segment, which includes both frac sand sales and IPS sales. Geographically, the company derives maximum revenue from United States, followed by Canada.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.